



STATEMENT

9th Meeting of the Intergovernmental Negotiating Body (INB)

18 MARCH 2024, GENEVA – Last week, the global biopharmaceutical industry, from both developed and developing countries, reiterated its [commitments to delivering equitable access](#) to essential medical countermeasures (MCMs).

Achieving equitable access requires a comprehensive solution and should not be based on linking access to pathogen samples and sequence data to benefit-sharing obligations in a transactional manner. Scientists need rapid and unconditional access to pathogens and data to quickly develop MCMs.

The [current negotiating text](#) is a step backward in finding practical and implementable solutions to improve pandemic preparedness and response (PPR). The revised text includes many disincentives for industry engagement, including with a PABS system. It is critical to preserve the innovation ecosystem and research incentives that were effective in the fight against COVID-19.

We reiterate again our full commitment to share our experience, evidence, and expertise to support Member States to find convergence by May.